overactive bladder syndrom. Bladder contracted
Conditions
Interventions
Intervention 1: Control group: Tolterodine, Tab. 2 mg Oral, q12h for 4 weeks. Intervention 2: Intervention group: Tadalafil, Tab. 20 mg Oral, qod for 4 weeks. Intervention 3: Control group: Placebo(gl
Treatment - Drugs
Placebo
Control group: Tolterodine, Tab. 2 mg Oral, q12h for 4 weeks
Intervention group: Tadalafil, Tab. 20 mg Oral, qod for 4 weeks
Control group: Placebo(glucose), Tab. 1 Number Oral, qod for 4 weeks
Sponsors
Vice-Research of Medical School of Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Female with urgency with or without urge incontinence; First presentation of disease; Nonmenpause; Age range between 18 and 50 years old. Exclusion criteria: Previous medication therapy; Abnormal ultrasonography of kidneys,ureters and bladder; Positive urine cultur; Diabetes; Identified norologic disorders; Age less than 18 years old; Age greater than 50 years old; Menopause.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of the symptoms severity. Timepoint: Before and 4 weeks after treatment. Method of measurement: ICIQ-OAB questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Sari motlagh
Tabriz University of Medical Sciences
Outcome results
None listed